دورية أكاديمية

Identification of a Blood-Based Protein Biomarker Panel for Lung Cancer Detection.

التفاصيل البيبلوغرافية
العنوان: Identification of a Blood-Based Protein Biomarker Panel for Lung Cancer Detection.
المؤلفون: El-Khoury, Victoria, Schritz, Anna, Kim, Sang-Yoon, Lesur, Antoine, Sertamo, Katriina, Bernardin, François, Petritis, Konstantinos, Pirrotte, Patrick, Selinsky, Cheryl, Whiteaker, Jeffrey R., Zhang, Haizhen, Kennedy, Jacob J., Lin, Chenwei, Lee, Lik Wee, Yan, Ping, Tran, Nhan L., Inge, Landon J., Chalabi, Khaled, Decker, Georges, Bjerkvig, Rolf
المصدر: Cancers; Jun2020, Vol. 12 Issue 6, p1629, 1p
مصطلحات موضوعية: BLOOD plasma, CANCER patients, LIQUID chromatography, LUNG tumors, MASS spectrometry, MOLECULAR diagnosis, PROTEINS, RISK assessment, STATISTICAL sampling, SMOKING, TUMOR markers, PROTEOMICS, RECEIVER operating characteristic curves, EARLY detection of cancer
مستخلص: Lung cancer is the deadliest cancer worldwide, mainly due to its advanced stage at the time of diagnosis. A non-invasive method for its early detection remains mandatory to improve patients' survival. Plasma levels of 351 proteins were quantified by Liquid Chromatography-Parallel Reaction Monitoring (LC-PRM)-based mass spectrometry in 128 lung cancer patients and 93 healthy donors. Bootstrap sampling and least absolute shrinkage and selection operator (LASSO) penalization were used to find the best protein combination for outcome prediction. The PanelomiX platform was used to select the optimal biomarker thresholds. The panel was validated in 48 patients and 49 healthy volunteers. A 6-protein panel clearly distinguished lung cancer from healthy individuals. The panel displayed excellent performance: area under the receiver operating characteristic curve (AUC) = 0.999, positive predictive value (PPV) = 0.992, negative predictive value (NPV) = 0.989, specificity = 0.989 and sensitivity = 0.992. The panel detected lung cancer independently of the disease stage. The 6-protein panel and other sub-combinations displayed excellent results in the validation dataset. In conclusion, we identified a blood-based 6-protein panel as a diagnostic tool in lung cancer. Used as a routine test for high- and average-risk individuals, it may complement currently adopted techniques in lung cancer screening. [ABSTRACT FROM AUTHOR]
Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:20726694
DOI:10.3390/cancers12061629